{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:08:41Z","timestamp":1745417321776},"reference-count":50,"publisher":"Walter de Gruyter GmbH","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec id=\"j_dmpt-2019-0022_s_999\">\n<jats:title id=\"d155763e10918\">Background<\/jats:title>\n<jats:p>Prolongation of the QTc interval may lead to life threatening arrhythmias. QTc prolongation is common in intensive care unit (ICU) patients. The objectives of this study were to identify the role of drug-drug interactions (DDIs) and other predictors (age, sex, cardiovascular diseases, and electrolyte abnormalities) in life threatening QTc prolongation in patients admitted to medical (M), surgical (S) and emergency (E) ICUs.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"j_dmpt-2019-0022_s_998\">\n<jats:title id=\"d155763e10927\">Methods<\/jats:title>\n<jats:p>This prospective, observational study included patients above the age of 18 years who were admitted to SICU, EICU, and MICU at a tertiary respiratory referral center. Electrocardiogram (ECG) monitoring was performed during the first 5 days of ICU admission. Risk factors and DDIs which were anticipated to be associated with the prolongation of the QTc interval were assessed for all patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"j_dmpt-2019-0022_s_997\">\n<jats:title id=\"d155763e10936\">Results<\/jats:title>\n<jats:p>Two hundred patients were included in the study. QTc prolongation occurred in 10.7% of patients and the majority of patients presenting with QTc prolongation had creatinine levels above 1.3 mg\/dL during their 5 days of ICU admission. Incidence of pharmacodynamic (PD) DDIs was significantly higher in patients with QTc prolongation vs. other patients. Creatinine levels above 1.3 mg\/dL and PD DDIs were associated with QTc prolongation during 5 days of ICU admission.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"j_dmpt-2019-0022_s_996\">\n<jats:title id=\"d155763e10945\">Conclusions<\/jats:title>\n<jats:p>High serum creatinine and PD DDIs can increase the risk of QTc prolongation in patients admitted to the ICU. QTc interval measurements should be performed prior to initiation or after starting any drug that is associated with QT prolongation, specifically in patients with the known risk factors.<\/jats:p>\n<\/jats:sec>","DOI":"10.1515\/dmpt-2019-0022","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T09:03:03Z","timestamp":1576832583000},"source":"Crossref","is-referenced-by-count":6,"title":["Drug interactions and creatinine levels are associated with QTc prolongation in intensive care units: a prospective, observational study"],"prefix":"10.1515","volume":"34","author":[{"given":"Zeinab","family":"Hosseinpoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behrooz","family":"Farzanegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyyed Reza","family":"Seyyedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Rajabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"Baniasadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref411","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/00325481.2018.1516106","article-title":"High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units","volume":"130","year":"2018","journal-title":"Postgrad Med"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1164\/rccm.200701-031OC","article-title":"Incidence and prognosis of sustained arrhythmias in critically ill patients","volume":"178","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","year":"2016","journal-title":"Can Pharm J"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1523-1755.2005.00072.x","article-title":"Electrocardiographic abnormalities and uremic cardiomyopathy","volume":"67","year":"2005","journal-title":"Kidney Int"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","year":"2007","journal-title":"Am Heart J"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/00325481.2018.1516106","article-title":"High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units","volume":"130","year":"2018","journal-title":"Postgrad Med"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","year":"2007","journal-title":"Ther Drug Monit"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14740\/jocmr3338w","article-title":"Impact of drug induced long QT syndrome: a systematic review","volume":"10","year":"2018","journal-title":"J Clin Med Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000493400","article-title":"Corrected QT interval prolongation in psychopharmacological treatment and its modulation by genetic variation","volume":"77","year":"2019","journal-title":"Neuropsychobiology"},{"key":"ref451","article-title":"QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications","volume":"13","year":"2018","journal-title":"PloS One"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1592\/phco.23.7.881.32730","article-title":"Clinical relevance and management of drug-related QT interval prolongation","volume":"23","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","year":"2007","journal-title":"Ther Drug Monit"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"ref181","article-title":"QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications","volume":"13","year":"2018","journal-title":"PloS One"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000493400","article-title":"Corrected QT interval prolongation in psychopharmacological treatment and its modulation by genetic variation","volume":"77","year":"2019","journal-title":"Neuropsychobiology"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0897190009356549","article-title":"Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors","volume":"23","year":"2010","journal-title":"J Pharm Pract"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1164\/rccm.200701-031OC","article-title":"Incidence and prognosis of sustained arrhythmias in critically ill patients","volume":"178","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1592\/phco.23.7.881.32730","article-title":"Clinical relevance and management of drug-related QT interval prolongation","volume":"23","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ckj\/sfs183","article-title":"QT interval in CKD and haemodialysis patients","volume":"6","year":"2013","journal-title":"Clin Kidney J"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"ref191","first-page":"210","article-title":"Drug-induced QT interval prolongation in the intensive care unit","volume":"12","year":"2017","journal-title":"Curr Clin Pharmacol"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2710.1998.00086.x","article-title":"Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes","volume":"23","year":"1998","journal-title":"J Clin Pharmacol Ther"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","year":"2016","journal-title":"Can Pharm J"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pds.1155","article-title":"Frequency of high-risk use of QT-prolonging medications","volume":"15","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcrc.2012.10.014","article-title":"Drug-drug interactions contributing to QT prolongation in cardiac intensive care units","volume":"28","year":"2013","journal-title":"J Crit Care"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/11598160-000000000-00000","article-title":"Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT-interval prolonging drugs","volume":"35","year":"2012","journal-title":"Drug Saf"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2125.2002.01627.x","article-title":"The significance of QT interval in drug development","volume":"54","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14740331003739188","article-title":"QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions","volume":"9","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","year":"2004","journal-title":"N Engl J Med"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14740\/jocmr3338w","article-title":"Impact of drug induced long QT syndrome: a systematic review","volume":"10","year":"2018","journal-title":"J Clin Med Res"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/CCM.0b013e318232db4a","article-title":"High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) study","volume":"40","year":"2012","journal-title":"Crit Care Med"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CCM.0000198106.54306.D7","article-title":"Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection","volume":"34","year":"2006","journal-title":"Crit Care Med"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2710.1998.00086.x","article-title":"Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes","volume":"23","year":"1998","journal-title":"J Clin Pharmacol Ther"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2125.2002.01627.x","article-title":"The significance of QT interval in drug development","volume":"54","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2165\/11598160-000000000-00000","article-title":"Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT-interval prolonging drugs","volume":"35","year":"2012","journal-title":"Drug Saf"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/clc.20768","article-title":"QT prolongation is an independent predictor of mortality in end-stage renal disease","volume":"33","year":"2010","journal-title":"Clin Cardiol"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","year":"2007","journal-title":"Am Heart J"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/clc.20768","article-title":"QT prolongation is an independent predictor of mortality in end-stage renal disease","volume":"33","year":"2010","journal-title":"Clin Cardiol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1517\/14740331003739188","article-title":"QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions","volume":"9","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcrc.2012.10.014","article-title":"Drug-drug interactions contributing to QT prolongation in cardiac intensive care units","volume":"28","year":"2013","journal-title":"J Crit Care"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1523-1755.2005.00072.x","article-title":"Electrocardiographic abnormalities and uremic cardiomyopathy","volume":"67","year":"2005","journal-title":"Kidney Int"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/CCM.0b013e318232db4a","article-title":"High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) study","volume":"40","year":"2012","journal-title":"Crit Care Med"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pds.1155","article-title":"Frequency of high-risk use of QT-prolonging medications","volume":"15","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CCM.0000198106.54306.D7","article-title":"Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection","volume":"34","year":"2006","journal-title":"Crit Care Med"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ckj\/sfs183","article-title":"QT interval in CKD and haemodialysis patients","volume":"6","year":"2013","journal-title":"Clin Kidney J"},{"key":"ref461","first-page":"210","article-title":"Drug-induced QT interval prolongation in the intensive care unit","volume":"12","year":"2017","journal-title":"Curr Clin Pharmacol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0897190009356549","article-title":"Drug-induced QTc-interval prolongation in the intensive care unit: incidence and predictors","volume":"23","year":"2010","journal-title":"J Pharm Pract"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/dmdi.2019.34.issue-4\/dmpt-2019-0022\/dmpt-2019-0022.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2019-0022\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:52:23Z","timestamp":1619041943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/dmpt-2019-0022\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":50,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1515\/dmpt-2019-0022","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]}}}